GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple MyelomaGlobeNewsWire · Sep 15, 2026
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy TranscriptSeeking Alpha · Sep 11, 2026
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026GlobeNewsWire · Sep 11, 2026
GT Biopharma Reports Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 14, 2026GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$2.00 | -$3.00 | Miss |
| May 21, 2026 | -$2.00 | -$0.11 | Beat |
| Mar 2, 2026 | -$5.50 | -$55.50 | Miss |
| Nov 13, 2025 | -$9.50 | -$0.83 | Beat |
| Aug 13, 2025 | -$17.00 | -$0.55 | Beat |
| May 21, 2025 | -$16.00 | -$0.33 | Beat |